Erudio Healtherudio.com
Drug
Capivasertib trials: what clinicians said in public
No HCP commentary report on a trial studying capivasertib yet. Erudio has found public clinician commentary on 6 clinical trials studying capivasertib, including BEGONIA, CAPItello-291, CAPItello-292 and GUNS. Each trial's page lists the podcasts, videos and posts found so far and the price of a report.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| CAPItello-291 NCT04305496 · AstraZeneca DeepView → | HR+/HER2- locally advanced or metastatic breast cancer | Phase 3 | Deep | View | |||
| BEGONIA NCT03742102 · AstraZeneca DeepView → | first-line metastatic triple-negative breast cancer | Phase 1/Phase 2 | Deep | View | |||
| CAPItello-292 NCT04862663 · AstraZeneca DeepView → | HR+/HER2- advanced breast cancer | Phase 3 | Deep | View | |||
| GUNS NCT04812366 · University of British Columbia DeepView → | high-risk localized prostate cancer | Phase 2 | Deep | View | |||
| DESTINY-Breast08 NCT04556773 · AstraZeneca DeepView → | HER2-low metastatic breast cancer | Phase 1 | Deep | View | |||
| CAPItello-281 NCT04493853 · AstraZeneca StandardView → | PTEN-deficient de novo metastatic hormone-sensitive prostate cancer | Phase 3 | Standard | View | |||